Education
About Us
Working with TipRanks
Follow Us
Renalytix (RNLXY)
OTHER OTC:RNLXY
Earnings Data
Report Date
Jun 17, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
―Last Year’s EPS
-0.16Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 18, 2025
|% Change Since: 10.00%
|Next Earnings Date:Jun 17, 2025
Earnings Call Sentiment|Positive
The call highlights significant achievements such as FDA approval, Medicare reimbursement, and strong revenue growth forecasts. However, challenges remain in scaling operations and international expansion.Company Guidance
In the Renalytix investor presentation, Executive Chairman Julian Baines outlined key growth metrics and future projections for the company. The fiscal year 2025 revenue is forecasted at $3.2 million, with expectations to rise to $8.4 million in the following year and $17 million subsequently. The company has achieved a 20% quarter-on-quarter revenue growth post-funding and has managed a 50% reduction in admin fees. Currently, 95% of Medicare claims are paid in under 30 days, and Medicare covers 52% of the tests at $950 each. Renalytix has expanded its customer base to over 800 independent ordering physicians and has processed over 15,000 clinical test results. The company's testing cancellation rate has significantly decreased from 24% to 8%, and the average turnaround time for test results has improved to under seven days. With cash reserves of $9.2 million and ongoing cost reductions, the business is strategically positioned for sustained growth, focusing heavily on expanding its hospital system partnerships and insurance coverage to further drive revenue and market penetration.FDA Approval and Medicare Reimbursement
Renalytix achieved the first-ever FDA-approved breakthrough designation prognostic test for kidney disease, with full Medicare reimbursement at $950 per test. This positions KidneyIntelX in a unique and uncontested market.
Revenue Growth and Forecast
The company is confident in achieving $3.2 million revenue for the current fiscal year, with forecasts of $8.4 million next year and $17 million thereafter. Renalytix has delivered on a 20% quarter-on-quarter revenue growth post-funding.
Commercial Testing Volume Increase
Commercial testing volume increased significantly from 60% to 82% in the prior period.
Cost Reductions Achieved
Renalytix has achieved a 50% reduction in admin fees, alongside other significant cost reductions.
Operational Improvements
Test turnaround times have improved to under seven days, and 95% of Medicare claims are now paid in under 30 days, enhancing cash flow.
Strategic Partnerships and Market Expansion
Renalytix is developing strategic partnerships and expanding its market reach, including collaborations with ACPNY hospital system and other potential pharma partnerships.
---
RNLXY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RNLXY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 18, 2025 | $0.20 | $0.24 | +20.00% |
| Nov 20, 2024 | $0.15 | $0.15 | 0.00% |
| Oct 01, 2024 | $0.21 | $0.21 | 0.00% |
| May 15, 2024 | $0.66 | $0.57 | -13.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Renalytix (RNLXY) report earnings?
Renalytix (RNLXY) is schdueled to report earning on Jun 17, 2025, TBA Not Confirmed.
What is Renalytix (RNLXY) earnings time?
Renalytix (RNLXY) earnings time is at Jun 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RNLXY EPS forecast?
Currently, no data Available
---